Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Mabxience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Teva and mAbxience Announce Global Licensing Deal for an Oncology Biosimilar Candidate
Details : mAbxience will leverage its expertise in biosimilar development to develop and produce the biosimilar product currently in development for the treatment of multiple oncology indications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Mabxience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Mabxience
Deal Size : Undisclosed
Deal Type : Partnership
Teva Expands Partnership with mAbxience for Additional Oncology Biosimilar
Details : mAbxience will lead the development and production of an anti PD-1 biosimilar and Teva will manage regulatory approvals and oversee commercialization of this oncology treatment.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Mabxience
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including MM, mantle cell lymphoma, and del (5q) myelodysplastic syndromes, follicular lymphoma and marginal zone lymphoma.
Product Name : Lenalid
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 03, 2023
Lead Product(s) : Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interleukin 2,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : CEL-SCI
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Multikine (leukocyte interleukin) is designed to help the immune system “see” the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.
Product Name : Multikine
Product Type : Protein
Upfront Cash : Inapplicable
December 09, 2022
Lead Product(s) : Interleukin 2,Cyclophosphamide,Indomethacin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : CEL-SCI
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
Details : Revlimid (lenalidomide capsules), a prescription medicine used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, is first generic version available in 5mg, 10mg, 15mg, and 25mg strengths, in the United States...
Product Name : Lenalidomide-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2022
Lead Product(s) : Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : AlivaMab
Deal Size : Undisclosed
Deal Type : Agreement
AlivaMab Discovery Services Announces Multi-Target Agreement with Teva Pharmaceuticals
Details : The programs will leverage the ADS discovery platform, which includes a suite of different immunization technologies that address challenging targets such as G-protein-coupled-receptors and high homology targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 14, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : AlivaMab
Deal Size : Undisclosed
Deal Type : Agreement
Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Prestige BioPharma Pte Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Details : The partnership includes the exclusive rights for Teva Israel to commercialize Tuznue™ (trastuzumab) in Israel, leveraging the company’s strong sales and marketing capabilities and experience in successfully bringing pharmaceutical products to market...
Product Name : Tuznue
Product Type : Antibody
Upfront Cash : Undisclosed
October 11, 2020
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Prestige BioPharma Pte Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership
Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market
Details : Under this partnership agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercializing the products in the U.S.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 08, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership